Mylan NV MYL tried to pour cold water on a report Friday it might be acquired by Teva Pharmaceutical Industries Ltd TEVA.
But Mylan jumped more than 4 percent recently to $69.70.
Mylan Executive Chairman Robert J. Coury said a merger with Teva would be "without sound industrial logic or cultural fit."
Coury added that such a deal would probably be blocked by antitrust regulators.
If any offer materialized, however, Coury said Mylan's board "would carefully consider it," acting in the best interests of Mylan and its shareholders.
Citing unnamed sources, Bloomberg said earlier that Teva is deliberating whether to make an offer.
Mylan's April 8 unsolicited $28.9 billion offer for Perrigo Co. PRGO is viewed by some investors as an incentive for Teva to make a bid.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.